Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9

Cancer Biotherapy and Radiopharmaceuticals

Volumn 20, Issue 5, 2005, Pages 534-546

  Modak, Shakeel ^a   Guo, Hong Fen ^a   Humm, John L ^a   Smith Jones, Peter M ^a   Larson, Steven M ^a   Cheung, Nai Kong V ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Pediatric solid tumors; Radioimmunodetection; Radioimmunotherapy; Rhabdomyosarcoma

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8H9; TOSYLCHLORAMIDE SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG UPTAKE; EPITHELIUM TUMOR; HUMAN; HUMAN CELL; ISOTOPE LABELING; MESENCHYMOMA; MOUSE; NEUROECTODERM TUMOR; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RHABDOMYOSARCOMA; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; EPITHELIUM; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; KINETICS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; RADIOIMMUNOTHERAPY; RHABDOMYOSARCOMA; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 27744447869     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2005.20.534     Document Type: Article

References (43)

1. Crist W, Gehan EA, Ragab AH, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995;13:610.
2. Koscielniak E, Harms D, Henze G, et al. Results of treatment for soft tissue sarcoma in childhood and adolescence: A final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 1999;17:3706.
3. Breneman JC, Lyden E, Pappo AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma-a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78.
4. Weigel BJ, Breitfeld PP, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001;23:272.
5. Ruymann FB, Grovas AC. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest 2000;18:223.
6. Cheung NKV, Kushner BH, Cheung IY, et al. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16:3053.
7. Cheung NK, Munn D, Kushner BH, et al. Targeted radiotherapy and immunotherapy of human neuroblastoma with G{-D2} specific monoclonal antibodies. Int J Radiat Appl Instr Part B, Nucl Med Biol 1988;16:111.
8. Cheung NK, Neely JE, Landmeier B, et al. Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma. J Nucl Med 1987;28:1577.
9. Cheung NK, Landmeier B, Neely J, et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2 specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst 1986;77:739.
10. Yeh SD, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med 1991;32:769.
11. Kramer K, Cheung NKV, Humm JL, et al. Targeted radioimmunotherapy for leptomeningeal cancer using 131-1-3F8. Med Pediatr Oncol 2000;35:716.
12. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189.
13. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: A novel multimodality therapy of high-risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001;36:227.
14. Wang NP, Marx J, McNutt MA, et al. Expression of myogenic regulatory proteins (myogenin and MyoD1) in small blue round cell tumors of childhood. Am J Pathol 1995;147:1799.
15. Kumar S, Perlman E, Harris CA, et al. Myogenin is a specific marker for rhabdomyosarcoma: An immunohistochemical study in paraffin-embedded tissues. Mod Pathol 2000;13:988.
16. Truong LD, Rangdaeng S, Cagle P, et al. The diagnostic utility of desmin. A study of 584 cases and review of the literature. Am J Clin Pathol 1990;93:305.
17. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup Rhabdomyosarcoma Study: Update for pathologists. Pediatr Dev Pathol 1998;1:550.
18. Gruchala A, Niezabitowski A, Wasilewska A, et al. Rhabdomyosarcoma. Morphologic, immunohistochemical, and DNA study. Gen Diagn Pathol 1997;142:175.
19. Garin-Chesa P, Fellinger EJ, Huvos AG, et al. Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence. Am J Pathol 1991;139:275.
20. Strother DR, Parham DM, Houghton PJ. Expression of the 5.1 H11 antigen, a fetal muscle surface antigen, in normal and neoplastic tissue. Arch Pathol Lab Med 1990;114:593.
21. Fujisawa T, Xu ZJ, Reynolds CP, et al. A monoclonal antibody with selective immunoreactivity for neuroblastoma and rhabdomyosarcoma. [abstr.] Proc AACR 1989;30:345.
22. Gattenloehner S, Vincent A, Leuschner I, et al. The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors. Am J Pathol 1998;152:437.
23. Kalebic T, Blakesley V, Slade C, Plasschaert S, Leroith D, Helman LJ. Expression of a kinase-deficient IGF-I-R suppresses tumorigenicity of rhabdomyosarcoma cells constitutively expressing a wild type IGF-I-R. Int J Cancer 1998;76:223.
24. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073.
25. Ricci C, Polito L, Nanni P, et al. HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J Immunother 2002;25:314.
26. Thomson B, Hawkins D, Felgenhauer J, et al. RT-PCR evaluation of peripheral blood, bone marrow, and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma. Bone Marrow Transpl 1999;24:527.
27. Athale UH, Shurtleff SA, Jenkins JJ, et al. Use of reverse transcriptase polymerase chain reaction for diagnosis and staging of alveolar rhabdomyosarcoma, Ewing sarcoma family of tumors, and desmoplastic small round cell tumor. J Pediatr Hematol Oncol 2001;23:99.
28. Mackall C, Berzofsky J, Helman LJ. Targeting tumor-specific translocations in sarcomas in pediatric patients for immunotherapy. Clin Orthop Relat Res 2000;373:25.
29. Rodeberg DA, Nuss RA, Heppelmann CJ, et al. Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma. Cancer Immunol Immunother 2005;54:526.
30. Modak S, Kramer K, Gultekin SH, et al. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 2001;61:4048.
31. Modak S, Gerald W, Cheung NK. Disialoganglioside GD2 and a novel tumor antigen: Potential targets for immunotherapy of desmoplastic small round cell tumor. Med Pediatr Oncol 2002;39:547.
32. Cheung NK, Saarinen U, Neely J, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642.
33. Cheung NK, Guo HF, Modak S, et al. Anti-idiotypic antibody as the surrogate antigen for cloning scFv and its fusion proteins. Hybrid Hybridomics 2002;21:433.
34. Cheung NK, Guo HF, Modak S, et al. Anti-idiotypic antibody facilitates scFv chimeric immune receptor gene transduction and clonal expansion of human lymphocytes for tumor therapy. Hybrid Hybridomics 2003;22:209.
35. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res 2000;60:5237.
36. Nilsson EE, Westfall SD, McDonald C, et al. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother Pharmacol 2002;49:93.
37. Merino ME, Navid F, Christensen BL, et al. Immunomagnetic purging of Ewing's sarcoma from blood and bone marrow: Quantitation by real-time polymerase chain reaction. J Clin Oncol 2001;19:3649.
38. Thanavala YM, Brown SE, Howard CR, et al. A surrogate hepatitis B virus antigenic epitope represented by a synthetic peptide and an internal image antiidiotype antibody. J Exp Med 1986;164:227.
39. Wagner U, Schlebusch hours, Kohler S, et al. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. Hybridoma 1997;16:33.
40. Onda M, Wang QC, Guo HF, et al. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Cancer Res 2004;64:1419.
41. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside G(D2)-positive tumors. Nucl Med Biol 1999;26:681.
42. Wolford ST, Schroer RA, Gohs FX, et al. Reference range data base for serum chemistry and hematology values in laboratory animals. J Toxicol Environ Health 1986;18:161.
43. Moore D. Hematology of the mouse. In: Schalm's Veterinary Hematology, 5th ed. Philadelphia: Lippincott, Williams and Wilkins, 2000:1219.